PI3Kα inhibitors that inhibit metastasis.

Oleg Schmidt-Kittler, Jiuxiang Zhu, Jian Yang, Guosheng Liu, William Hendricks, Christoph Lengauer, Sandra B. Gabelli, Kenneth W. Kinzler, Bert Vogelstein, David L. Huso, Shibin Zhou

Research output: Contribution to journalArticlepeer-review

Abstract

Previous genetic analyses have suggested that mutations of the genes encoding PI3Kα facilitate invasion and metastasis but have less effect on primary tumor growth. These findings have major implications for therapeutics but have not been factored into pre-clinical drug development designs. Here we show that the inhibition of PI3Kα by newly designed small molecule inhibitors prevented metastasis formation in mice but had much less effect on the growth of subcutaneous xenografts or primary intra-abdominal tumors. These data support the idea that PI3Kα plays an important role in the metastatic process and suggest a more informed strategy for selecting drugs worthy of further development for clinical application.

Original languageEnglish (US)
Pages (from-to)339-348
Number of pages10
JournalOncotarget
Volume1
Issue number5
DOIs
StatePublished - Sep 2010

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'PI3Kα inhibitors that inhibit metastasis.'. Together they form a unique fingerprint.

Cite this